Acerta

Frazier hits $419M for early-stage biotech investments

California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science work.

Ben Adams Nov 1, 2017 5:00am

Bristol-Myers, Johnson & Johnson help BGV top fund goal

Oct 31, 2017 8:25am

AstraZeneca buy Acerta faked cancer drug data, company admits

Oct 16, 2017 9:57am